Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCPED1249


An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Principal Investigator(s)

Howard Katzenstein


  • Protocol No. VICCPED1249
  • Open Date: 08/06/2012
  • Staging: N/A
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: - Provide palliative therapy with MIBG for patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma - Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma, pheochromocytoma, or paraganglioma
  • Disease Sites: Pediatric Solid Tumors; Neuroblastoma (Pediatrics)
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: 131-MIBG; Iobenguane Sulfate
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01590680
  • Secondary Protocol No: Not Specified


None Provided.


Not provided. Please call for more information.